Sugi Predict

Sugi Predict / Compounds / SCHEMBL1122272

SCHEMBL1122272

SCHEMBL1122272

CC1=NN(c2ccccc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 2/20 0.59
▸ MAPT P10636 7/20 0.58
▸ MAPK1 P28482 6/20 0.58
▸ KDM4E B2RXH2 5/20 0.58
▸ RAB9A P51151 5/20 0.58
▸ NPC1 O15118 4/20 0.58
▸ L3MBTL1 Q9Y468 3/20 0.58
▸ TDP1 Q9NUW8 2/20 0.58
▸ GLA P06280 2/20 0.58
▸ MEN1 O00255 8/20 0.43
▸ KMT2A Q03164 8/20 0.43
▸ ALDH1A1 P00352 6/20 0.43
▸ GAA P10253 5/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ PTGS1 P23219 2/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CHRM2 P08172 1/20 0.43
▸ CHRM1 P11229 1/20 0.43
▸ TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31065089 0.88 MAOB (0.51) MAOBMAPTMAPK1KDM4ERAB9A
SCHEMBL13260410 0.83 MAOB (0.54) MAOBMAPTMAPK1KDM4ERAB9A
SCHEMBL20285407 0.80 MEN1 (0.41) MAOBMAPTMAPK1KDM4ERAB9A
SCHEMBL16659465 0.80 CYP2A6 (0.45) MAOBMAPTMAPK1KDM4ERAB9A
SCHEMBL30451094 0.76 KDM4E (0.42) MAOBMAPTMAPK1KDM4ERAB9A
SCHEMBL7719905 0.75 ALOX5 (0.58) MAOBMAPTMAPK1KDM4ERAB9A
SCHEMBL8911866 0.75 MAPT (0.58) MAOBMAPTMAPK1KDM4ERAB9A
SCHEMBL2730663 0.75 MAPT (0.58) MAOBMAPTMAPK1KDM4ERAB9A
Phenidone SCHEMBL9670254 0.75 MAOB (0.59) MAOBMAPTMAPK1KDM4ERAB9A
SCHEMBL17801328 0.75 MAPT (0.63) MAOBMAPTMAPK1KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116370471-B Be used for cerebral apoplexy in (a) and (b) a composition of (b) 山东奥萨制药有限公司 2025-03-14 — — CN claimed
CN-116370471-A Composition for cerebral apoplexy 深圳泰乐德中药有限公司 2023-07-04 — — CN claimed
WO-2023093399-A1 BENZOTHIAZOLE-PARENT-BASED FLUORESCENT PROBE FOR DETECTION OF PALLADIUM IONS, AND PREPARATION METHOD THEREFOR AND USE THEREOF 江苏科技大学 2023-06-01 — — WO claimed
CN-115746160-A Method for reducing viscosity of polysaccharide 南方海洋科学与工程广东省实验室(广州) 2023-03-07 — — CN claimed
CN-113912596-B Benzothiazole matrix-based palladium ion detection fluorescent probe and preparation method and application thereof 江苏科技大学 2022-12-02 — — CN claimed
EP-0378373-B1 Photohardenable compositions and their use in producing images MEAD CORP (US) 1997-03-05 — — EP claimed
EP-0378373-A2 Photohardenable compositions and their use in producing images THE MEAD CORPORATION (US) 1990-07-18 — — EP claimed
CN-120131642-A Stable pharmaceutical composition 先声药业有限公司 2025-06-13 — — CN disclosed
US-12320793-B2 Analysis method of 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, treatment for amyotrophic lateral sclerosis, inhibition of progression of amyotrophic lateral sclerosis, and method of producing medicament containing 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient MITSUBISHI TANABE PHARMA CORPORATION (JP) 2025-06-03 — — US disclosed
CN-119896666-A Stable pharmaceutical composition 先声药业有限公司 2025-04-29 — — CN disclosed
CN-119730851-A Edaravone oral preparation and improved preparation method thereof BDR制药国际私人有限公司 2025-03-28 — — CN disclosed
CN-119661441-A Pyrazolone compound, preparation method and application thereof 新乡医学院 2025-03-21 — — CN disclosed
CN-119661441-A Pyrazolone compound, preparation method and application thereof 新乡医学院 2025-03-21 — — CN disclosed
US-6464732-B2 HAIR DYE MIXTURE L'OREAL S.A. (FR) 2002-10-15 — — US disclosed
EP-0378373-B1 Photohardenable compositions and their use in producing images MEAD CORP (US) 1997-03-05 — — EP disclosed
US-5079126-A Pyrazoline-5-one compound, reduction of reciprocity failure, imaging method, microcapsules coated on support THE MEAD CORPORATION (US) 1992-01-07 — — US disclosed
EP-0378373-A2 Photohardenable compositions and their use in producing images THE MEAD CORPORATION (US) 1990-07-18 — — EP disclosed
EP-0088963-A1 Process for the preparation of pyrazoles by catalytic dehydrogenation of pyrazolines BASF Aktiengesellschaft (DE) 1983-09-21 — — EP disclosed
US-4211436-A Pressure-sensitive recording material BAYER AKTIENGESELLSCHAFT (DE) 1980-07-08 — — US disclosed
US-4115413-A ACID FREE BAYER AKTIENGESELLSCHAFT (DE) 1978-09-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12320793-B2 Analysis method of 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, treatment for amyotrophic lateral sclerosis, inhibition of progression of amyotrophic lateral sclerosis, and method of producing medicament containing 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient SMN1; SMN2, PARK7, PMP22 MAOB 1965/4885MAPT 39/4885MAPK1 297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.